5 Proven Facts About the Blood Test Autism Spectrum Disorder Algorithm
A follow up study from Rensselaer Polytechnic Institute has confirmed the remarkable success of a blood test autism spectrum disorder detection method that uses metabolite patterns to predict whether a child has ASD with 88% accuracy. Published in Bioengineering and Translational Medicine, the research builds on a 2017 study and validates the original findings using an entirely independent dataset. According to the Mayo Clinic, most children are not diagnosed with ASD until after age 4, despite the fact that diagnosis is possible as early as 18 to 24 months. Earlier detection leads directly to earlier intervention and better long term outcomes.
Why a Physiological Test for Autism Matters
Current ASD diagnosis depends entirely on clinical observation, which introduces subjectivity and delays. A blood test autism spectrum disorder tool that supports a clinician’s diagnostic process could lower the average age of diagnosis significantly, giving children access to early intervention services during the most critical window of brain development.
Lead author Juergen Hahn, systems biologist, professor, and head of the Rensselaer Polytechnic Institute Department of Biomedical Engineering, described the results as extremely promising. The approach does not search for a single biomarker but instead uses big data techniques to identify patterns across multiple metabolites connected to two cellular pathways with suspected links to ASD: the methionine cycle and the transsulfuration pathway.
5 Proven Facts About the Blood Test Autism Spectrum Disorder Method
1. The Algorithm Predicts ASD With 88% Accuracy
When applied to an independent dataset of 154 children with autism from the Arkansas Children’s Research Institute, the blood test autism spectrum disorder predictive algorithm correctly identified ASD in 88% of cases. This result closely mirrors the original 2017 study, which achieved accuracy rates of 96.1% for typically developing children and 97.6% for the ASD cohort.
2. The Original Study Analyzed 149 Children Across 24 Metabolites
The foundational blood test autism spectrum disorder research analyzed data from 149 individuals, approximately half of whom had been previously diagnosed with ASD. For each participant, Hahn obtained data on 24 metabolites related to the two cellular pathways. Using a cross validation approach, the algorithm was tested against each individual in the dataset after being trained on the remaining participants.
3. The Follow Up Used an Independent Dataset to Confirm Results
To validate the original findings, Hahn and his team searched for existing datasets that included the relevant metabolites rather than conducting new clinical trials. The replication study used only 22 of the original 24 metabolites because two were unavailable in the new dataset. Despite this limitation, the blood test autism spectrum disorder algorithm maintained strong predictive performance, confirming the robustness of the approach.
4. The Accuracy Gap Between Studies Is Explained
The difference between the original accuracy rate and the 88% result in the replication study is attributable primarily to the two missing metabolites, both of which had been strong predictors in the original model. This finding reinforces the importance of metabolite completeness in future implementations of the blood test autism spectrum disorder platform and provides a clear path for further refinement.
5. Clinical Trials and Commercial Availability Are the Next Steps
Hahn has stated explicitly that this is an approach he would like to see move forward into clinical trials and ultimately into a commercially available test. The high degree of accuracy achieved using data collected years apart from the original dataset demonstrates that the method is stable and reproducible across different populations and time periods.
Why This Research Advances Early ASD Diagnosis
Approximately 1.7% of all children are diagnosed with autism spectrum disorder, according to the Centers for Disease Control and Prevention. The gap between when diagnosis is possible and when it typically occurs costs children years of early intervention access. A validated blood test autism spectrum disorder tool would fundamentally change that timeline by giving clinicians an objective physiological data point to support their evaluations.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active neurodevelopmental and pediatric studies, visit our patient active studies page.